Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that neoadjuvant chemotherapy followed by interval debulking surgery led to better quality of life and lower perioperative morbidity compared to primary debulking surgery in advanced epithelial ovarian cancer patients with high tumor load.

The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.

This study reported that 1% bexarotene gel was well tolerated and possibly effective for inducing partial hair regrowth in alopecia areata, but more rigorous trials are needed to confirm its efficacy.

This study found that dexamethasone-loaded Eudragit® L 100 nanoparticles displayed controlled drug release depending on pH levels, with minimal toxicity to human fibroblasts.

This study found that the novel drug VDC-1101 showed a 45% objective response rate in treating canine cutaneous T-cell lymphoma, offering a potential treatment option for this challenging disease.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

This study found that the pH dependency of rat steroid 5α-reductase type II isozyme significantly affects its kinetic properties, including Vmax and Km, suggesting past discrepancies in literature may arise from these pH variances during assays.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

This study found that RALF peptides, through liquid-liquid phase separation, form condensates with pectin and other proteins, playing a pivotal role in plant development and stress response regulation.

This study found that elagolix treatment did not normalize the ovulatory cycle in patients with polycystic ovarian syndrome.

This study found that paclitaxel poliglumex showed limited effectiveness and was relatively well tolerated in post-menopausal women with advanced NSCLC, suggesting further testing of this treatment may not be justified.

In this study, safusidenib erbumine was evaluated for its efficacy and safety in patients with untreated IDH1-mutated WHO grade 2 gliomas, achieving a 44.4% objective response rate and 87.9% 24-month event-free probability, but with some mild to moderate adverse effects.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

This study found that a 5% gel with hydroalcoholic extract from black pop bean integument may have a photoprotective effect in mice exposed to UV-C radiation.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This study found that both PRP injections and microneedling treatments significantly improved hair count and thickness in patients with androgenetic alopecia, without significant differences between the two methods. Microneedling also enhanced patient satisfaction and treatment tolerance.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

In this study, intrathecal progesterone administration initially worsened mechanical allodynia in mice after nerve injury, but later reduced pain when applied during the maintenance phase, highlighting distinct roles for cytochrome P450c17 and 5α-reductase in neuropathic pain modulation.

In this study, a strong positive correlation was found between clinician-reported and patient-reported measures for assessing eyebrow and eyelash hair loss in patients with severe alopecia areata, indicating high agreement during treatment with baricitinib over 52 weeks.

This study found that the 5α-reductase inhibitor finasteride affected phasic and tonic GABA A receptor-mediated currents differently in the thalamic reticular and ventrobasal nuclei of mice, suggesting endogenous neurosteroid modulation of these receptors.

St. John’s wort changes how finasteride works in the body, possibly affecting its effectiveness.

This study found that telogen effluvium occurred in two subjects taking 500 mg of mefloquine weekly, and gastrointestinal intolerance was observed at higher doses in additional acute studies.

This study found that while MK-0773 significantly increased lean body mass in sarcopenic frail elderly women, it did not significantly improve muscle strength or physical function compared to placebo.

FGF18 helps keep hair in its resting phase, affecting hair growth cycles.

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This study found that injecting PDGF-AA and -BB into mouse skin immediately triggered the hair growth cycle's anagen phase, suggesting potential treatment options for certain types of alopecia.

This study suggests that applying topical Tempol to the scalp before whole brain radiation may protect against radiation-induced alopecia and is safe and well-tolerated.

This study identified a distinct "exogen" phase in the hair cycle during which hair shedding occurs, primarily coupled with the anagen phase, rather than as part of the telogen phase.